Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (261-270 of 419) with videos related to

Pageof 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Cancer|July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinomaAndrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of Anthranilic Acid Derivatives as Antagonists of the Pro-Inflammatory Orphan G Protein-Coupled Receptor GPR17Nader M Boshta, Michael Lewash, Meryem Köse, et al.
The American Journal of Surgical Pathology|January 21, 2014
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistryYing-Bei Chen, A Rose Brannon, Antoun Toubaji, et al.
Immunity|June 5, 2012
Caspase-11 promotes the fusion of phagosomes harboring pathogenic bacteria with lysosomes by modulating actin polymerizationAnwari Akhter, Kyle Caution, Arwa Abu Khweek, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research networkA Ari Hakimi, Irina Ostrovnaya, Boris Reva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Pageof 42

Showing results (261-270 of 419) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Cancer|July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinomaAndrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of Anthranilic Acid Derivatives as Antagonists of the Pro-Inflammatory Orphan G Protein-Coupled Receptor GPR17Nader M Boshta, Michael Lewash, Meryem Köse, et al.
The American Journal of Surgical Pathology|January 21, 2014
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistryYing-Bei Chen, A Rose Brannon, Antoun Toubaji, et al.
Immunity|June 5, 2012
Caspase-11 promotes the fusion of phagosomes harboring pathogenic bacteria with lysosomes by modulating actin polymerizationAnwari Akhter, Kyle Caution, Arwa Abu Khweek, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research networkA Ari Hakimi, Irina Ostrovnaya, Boris Reva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Pageof 42